A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition
Cancer Reports · 2026
DOI: 10.1002/cnr2.70661 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2026. Verfasst von Aleksey Chernev und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Sergey Berezin Medical Institute, St. Petersburg, Russian Federation. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, DNA Polymerase II, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hepatoid adenocarcinoma of the lung (HAL) is a rare form of lung cancer with histological and morphological properties of hepatocellular carcinoma, characterized by an aggressive course of the disease and unfavorable prognosis. Given the rarity of the pathology and the lack of unambiguous therapeutic protocols, descriptions of clinical cases of HAL deserve attention. Case We describe a case of metastatic HAL in a 61‐year‐old patient, harboring a mismatch repair deficiency associated with the loss of PMS2 protein expression. Molecular‐genetic study identified several oncogenic variants including PMS2 p.Arg421Ter, PMS2 p.Arg107Trp, and POLE p.Pro286Arg and confirmed their somatic status. The laboratory findings clinically justified the use of immunotherapy with pembrolizumab, which afforded stabilization of the disease according to computed tomography data and complete tumor response according to morphological examination data.
Conclusion
The presented case highlights the room for immunotherapy in the highly aggressive HAL. The POLE p.Pro286Arg missense mutation has been attributed as a predictor for immune checkpoint inhibition efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Sergey Berezin Medical Institute, St. Petersburg, Russian Federation.
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
ORCID-Profile: Aleksey Chernev, Alina Kaurtseva, Ruslan Abasov, Gulnara Abdrakova, Natalia Usman, Alexander Druy, Grigory Raskin
Zitieren
APA
Chernev, A., Kaurtseva, A., Abasov, R., Enikeev, R., Gegelia, N., Abdrakova, G., Usman, N., Druy, A., & Raskin, G. (2026). A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition. Cancer Reports. https://doi.org/10.1002/cnr2.70661
Vancouver
Chernev A, Kaurtseva A, Abasov R, Enikeev R, Gegelia N, Abdrakova G, et al. A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition. Cancer Reports. 2026. doi:10.1002/cnr2.70661
BibTeX
@article{Chernev2026,
author = {Chernev, Aleksey and Kaurtseva, Alina and Abasov, Ruslan and Enikeev, Rafael and Gegelia, Nina and Abdrakova, Gulnara and Usman, Natalia and Druy, Alexander and Raskin, Grigory},
title = {A POLE P286R ‐Mutated Hepatoid Adenocarcinoma of the Lung Showing Substantial Response to Immune Checkpoint Inhibition},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70661}
}
EUVIMED